Highlights ■ Vendor Neutral Archive implementation has an return on investment of 5.63% in the first year and 10.12% after three years. ■ At least 11,500 exams are needed annually for a positive return on investment in the first year after implementation. ■ Vendor Neutral Archive enhances interoperability and efficiency by standardizing and centralizing image storage. ■ Scalability is key: higher adoption of Vendor Neutral Archive leads to greater financial and operational benefits. ABSTRACT Objective: To conduct an ex-ante cost-benefit […]

Highlights ■ Matching methodologies may reduce bias in economic evaluations. ■ Liver transplantation within the Proadi-SUS context has an incremental cost-effectiveness ratio below the Health Technology Incorporation in the Brazilian Health System threshold. ■ The patients who received transplant had a median survival of 10.1 years after list enrollment. ■ The mean cost per transplanted patient was US$ PPP 162,821.96. ABSTRACT Objective: To estimate the incremental cost and survival of patients on the liver transplantation waiting list who were referred […]

ABSTRACT Objective Human epidermal growth factor receptor 2 (HER2) overexpression occurs in up to 30% of breast cancer cases. Ado-trastuzumab emtansine (T-DM1) is approved to treat residual HER2-positive breast cancer after neoadjuvant therapy. The aim of this study was to determine the quality-adjusted time with symptoms or toxicity and without symptoms or toxicity (Q-TWiST) of T-DM1 compared to trastuzumab for residual invasive HER2-positive breast cancer. Methods The authors developed an analytical model extracting individual patient data and estimated invasive disease-free […]

ABSTRACT Objective: To evaluate the outcomes and costs associated with surgery versus sclerotherapy as treatment of hydroceles. Methods: A total of 53 men consecutively treated for hydrocele at our organization, between December 2015 and June 2019, were retrospectively analyzed (39 with Jaboulay technique and 14 with sclerotherapy). All charts were reviewed, assessing clinical data, ultrasound findings, surgical data, and post-procedure outcomes. The hospital finance department calculated the cost of outpatient evaluation, complementary tests, supplies, drugs, and professionals’ costs throughout all […]

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted […]